Literature DB >> 34306932

Delaying Postoperative Radiotherapy in Low-Grade Esthesioneuroblastoma: Is It Worth the Wait?

Satoshi Kiyofuji1,2, Vijay Agarwal1, Joshua D Hughes1, Robert L Foote3, Jeffrey R Janus4, Eric J Moore4, Caterina Giannini5, Michael J Link1,4, Jamie J Van Gompel1,4.   

Abstract

Background  Consensus in timing of radiotherapy is yet to be established in esthesioneuroblastoma (ENB). Objective  This study was aimed to investigate if planned adjuvant radiotherapy improves tumor control after complete margin negative resection of low Hyams' grade (1 or 2) ENB. Methods  A retrospective review of patients with pathologically confirmed negative margin resection of Kadish's stage B or C and Hyams' grade 1 and 2 ENBs was conducted. Seventeen patients meeting the criteria were divided into the following two groups for cohort study: (1) those who underwent planned immediate postoperative adjuvant radiotherapy (IR group) and (2) those who did not (delayed radiotherapy [DR] group). Results  The IR group included nine patients (Kadish's stage B in one and stage C in eight; Hyams' grade 1 in two and grade 2 in seven). Mean follow-up was 140.8 months. Seven patients (78%) had disease progression (DP) at a median of 88 months (four with cervical lymph node metastasis [CLNM], one with distant metastasis, and two with both local recurrence and CLNM). One patient experienced frontal lobe abscess. The DR group included eight patients (Kadish's stage B in six and stage C in two; all Hyams' grade 2). Mean follow-up was 123.3 months. Four (50%) patients who developed DP (all local recurrence) were salvaged with surgery and adjuvant radiotherapy at a median of 37.5 months. There was no statistically significant difference in DP rate ( p  = 0.23), time to DP ( p  = 0.26), or the local tumor control rate ( p  = 0.23). Conclusion  In our limited cohort, immediate postoperative radiotherapy did not demonstrate superiority in tumor control, although risk of radiotherapy toxicity appears low. Thieme. All rights reserved.

Entities:  

Keywords:  craniofacial resection; esthesioneuroblastoma; intensity-modulated radiation therapy; olfactory neuroblastoma; surgical treatment

Year:  2020        PMID: 34306932      PMCID: PMC8289555          DOI: 10.1055/s-0040-1708854

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  39 in total

Review 1.  Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.

Authors:  E A McElroy; J C Buckner; J E Lewis
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

2.  Esthesioneuroblastoma: endonasal endoscopic treatment.

Authors:  Paolo G Castelnuovo; Giovanni Delù; Federica Sberze; Andrea Pistochini; Cristhian Cambria; Paolo Battaglia; Maurizio Bignami
Journal:  Skull Base       Date:  2006-02

3.  Outcomes of Sinonasal Cancer Treated With Proton Therapy.

Authors:  Roi Dagan; Curtis Bryant; Zuofeng Li; Daniel Yeung; Jeb Justice; Peter Dzieglewiski; John Werning; Rui Fernandes; Phil Pirgousis; Donald C Lanza; Christopher G Morris; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-12       Impact factor: 7.038

4.  Radiosurgery is an Effective Treatment for Recurrent Esthesioneuroblastoma: A Multicenter Study.

Authors:  Jamie J Van Gompel; Michael J Link; Jason P Sheehan; Zhiyuan Xu; David Mathieu; Hideyuki Kano; L Dade Lunsford
Journal:  J Neurol Surg B Skull Base       Date:  2014-06-04

Review 5.  When, how and why to treat the neck in patients with esthesioneuroblastoma: a review.

Authors:  Adam M Zanation; Alfio Ferlito; Alessandra Rinaldo; Mitchell R Gore; Valerie J Lund; Kibwei A McKinney; Carlos Suárez; Robert P Takes; Anand K Devaiah
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-13       Impact factor: 2.503

6.  IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival.

Authors:  Fréderic Duprez; Indira Madani; Lieve Morbée; Katrien Bonte; Philippe Deron; Vilmos Domján; Tom Boterberg; Werner De Gersem; Wilfried De Neve
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-10-24       Impact factor: 7.038

Review 7.  Endoscopic management of Esthesioneuroblastoma: Our experience and review of the literature.

Authors:  Georgios Klironomos; Lior Gonen; Karolyn Au; Eric Monteiro; Alireza Mansouri; Mazda Keki Turel; Ian Witterick; Alan Vescan; Gelareh Zadeh; Fred Gentili
Journal:  J Clin Neurosci       Date:  2018-10-16       Impact factor: 1.961

8.  The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma.

Authors:  Gurvinder Kaur; Ari J Kane; Michael E Sughrue; Michelle Madden; Michael C Oh; Matthew Z Sun; Michael Safaee; Ivan El-Sayed; Manish Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2012-12-21       Impact factor: 1.961

9.  Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival.

Authors:  Jamie J Van Gompel; Caterina Giannini; Kerry D Olsen; Eric Moore; Manolo Piccirilli; Robert L Foote; Jan C Buckner; Michael J Link
Journal:  J Neurol Surg B Skull Base       Date:  2012-10

10.  Patterns of failure and outcome in esthesioneuroblastoma.

Authors:  Fernando L Dias; Geraldo M Sa; Roberto A Lima; Jacob Kligerman; Marlos P Leoncio; Emilson Q Freitas; Jose Roberto N Soares; Roberto Alfonso Arcuri
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.